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cardiologists assumed the surgical risk as too high.(9,10) This sum-
mation is usually based on the existence of co-morbidities such as 
low left ventricular ejection fraction, pulmonary disease or pre-
vious cardiac surgery. From a surgeon’s point of view, the assess-
ment of surgical risk is not always appropriate and many of these 
patients are still good candidates for conventional AVR. But there 
is a defined group of patients with a remarkably higher risk profile 
where conventional AVR with the use of cardio-pulmonary bypass 
and cardioplegic arrest should be avoided. For this subgroup of 
patients at high risk, transcatheter aortic valve implantation (TAVI) 
is a truly minimally invasive alternative treatment option that avoids 
cardio-pulmonary bypass, sternotomy and cardioplegic arrest. 
THE DEVELOPMENT OF TRANSCATHETER 
AORTIC VALVE IMPLANTATION
The first successful transcatheter aortic valve implantation was 
performed by Alain Cribier and his team in a patient with severe 
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INTRODUCTION
Aortic stenosis (AS) is the most common acquired heart valve 
disease in the Western world, which stays asymptomatic for a long 
time, but with rapid progression once it becomes symptomatic. The 
one-year mortality for medical treatment varies around 50% after 
first symptoms appear in patients with severe aortic stenosis.(1,2) 
The gold standard for the treatment of patients suffering from 
severe symptomatic AS is conventional surgical aortic valve 
replacement (AVR), which improves both symptoms and survival. 
The conventional AVR via sternotomy and using cardio pulmonary 
bypass is a routine procedure in cardiac surgery with very good 
results.(3) Some new developments, such as minimally invasive 
approaches to the aortic valve using a partial upper sternotomy or 
parasternal intercostal incision and new generation tissue valves 
have improved the results after conventional AVR.(4,5)
An increase in average life expectancy results in an increasing 
number of elderly patients with severe AS. The patient’s age alone 
is not an independent risk factor for conventional AVR and it can 
still be performed in octogenarians with a 30-day mortality around 
5-10%. Therefore, isolated advanced age should not be seen as a 
contra-indication for conventional AVR.(6-8)
Despite the good results for conventional AVR, there are still at 
least one third of elderly patients with severe AS who are not 
referred for cardiac surgery due to the fact that their referring 
Transcatheter aortic valve implantation (TAVI) has evolved 
into a routine procedure for elderly high-risk patients with 
severe aortic stenosis in specialised centres. It can be per-
formed via a transfemoral or a transapical approach. Both 
approaches are truly minimally invasive and avoid the use of 
cardio-pulmonary bypass and cardioplegic arrest. TAVI is 
associated with good outcome and acceptable complication 
rates. The outcome of TAVI has improved over the last few 
years as centres became more experienced in the pro-
cedure. Up to now there is no clear evidence-based benefi t 
for one or the other approach. A careful patient selection 
for each approach is therefore crucial for good results.
Both procedures should be performed by a heart team of 
cardiologists, cardiac surgeons and cardiac anaesthetists. 
The knowledge the cardiac surgeons gained over the last 
decades by treating aortic stenosis with conventional aortic 
valve replacement is very important in TAVI procedures: 
Not only in terms of the procedure itself, but also for pre-
operative patient screening.
TAVI must be approached as a team effort where cardi-
ologists and cardiac surgeons play an equal role and should 
not be performed without a cardiac surgeon.  
SAHeart 2012; 9:32-38
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aortic stenosis at high surgical risk in 2002.(11) With this approach it 
was possible to implant an aortic bioprostheses fixed on a stent 
within the native stenotic aortic valve, starting with an antegrade 
transseptal approach. The transseptal approach was associated with 
different complications and potential risks such as pericardial 
tamponade, mitral valve incompetence and haemodynamic instabi-
lities leading to acute procedural mortality.(12) These potential com-
plications led to the introduction of the retrograde transfemoral 
approach.(12) 
Limitations of the initial experience with the transfemoral approach 
were the sheath diameters of 22 - 24 French. These large sheath 
diameters led to major vascular complications in some cases, 
especially because the high risk TAVI patients often have calcified 
femoral vessels. The incidence of serious vascular complications 
after transfemoral approach including retroperitoneal haematoma, 
femoral artery dissection, aneurysms and major bleeding varies 
between 10 and 16%.(1,17) The current sheath sizes are reduced to 
18 French and a new expandable sheath with a 16 French diameter 
(eSheathTM, Edwards Lifesciences) has been introduced. The smaller 
sheath diameters may reduce the incidence of major vascular 
complications. Furthermore calcification often extends up to the 
aortic arch, which has to be crossed by the transfemoral devices. 
This led to a stroke rate of up to 10%.(13) Some cardiac surgeons 
realised that an alternative surgical approach for TAVI avoiding the 
major complications of the transfemoral approach was necessary. 
Initial animal studies were performed and the feasibility of the 
antegrade transapical access was proven.(14) The first minimally 
invasive transapical aortic valve implantations (TA-AVI) in selected 
high-risk patients were performed in 2006.(15,16)
INDICATION FOR TAVI
Until now there have been no stringent guidelines for TAVI 
indication. A position statement from the European Association of 
Cardio-Thoracic Surgery (EACTS) and the European Society of 
Cardiology (ESC), in collaboration with the European Association 
of Percutaneous Cardiovascular Interventions (EAPCI) offers some 
recommendations for potential TAVI patients.(17) In summary TAVI 
should be reserved for high risk patients presenting with a logistic 
EuroSCORE >20% and/or STS-score >10%. TAVI might also be 
a treatment option for patients with risk factors that are not 
represented in both of the scores such as porcelain aorta,(18) patent 
bypass grafts and patients with liver cirrhosis. After introducing the 
so-called vale-in-valve TAVI it is also possible to implant a trans-
catheter valve inside a degenerated xenograft.(19-21)
Besides the high-risk profile, patients who should undergo TAVI 
need to fulfil some anatomical criteria. In Europe 2 different types 
of TAVI valves are commercially available: The Medtronic 
CoreValve® for retrograde transfemoral (or transsubclavian/trans-
aortic) access only and the Edwards SAPIEN™ which can be 
implanted transfemorally or transapically. Both TAVI devices are 
available in limited prosthesis sizes and their sheaths for the 
transfemoral access are at least 18 French. Therefore pre-operative 
imaging including transoesophageal echocardiography (TEE) and 
computed tomography (CT) is very important to evaluate and 
measure the patient’s anatomical conditions including aortic valve 
anatomy, femoral artery diameter and distance of the coronary 
ostia to the aortic annulus. The diameter of the native aortic annulus 
should be between 18mm and 28mm (Figure 1), the femoral 
vessels should have a diameter of at least 6mm for the transfemoral 
approach and the distance between the aortic annulus and the 
coronary ostia should be at least 10mm to avoid an occlusion of 
the coronaries (Figure 2).
Certainly, a too large or a too small annulus diameter, as well as 
too short distance between the aortic annulus and the coronary 
ostia are contra-indications for TAVI as it is technically impossible 
or high risk to perform the procedure. In the initial TAVI experience 
a native bicuspid aortic valve was viewed as a contra-indication, 
but subsequently some successful TAVI procedures have been 
performed in patients with a bicuspid aortic valve.(22,23)
VALVE TYPES
There are 2 different types of TAVI valves commercially available in 
Europe: 
 ■ The Medtronic CoreValve® is a self-expandable porcine peri-
cardial valve on a nitinol stent. It is available in two sizes, a 
26mm and a 29mm valve. The delivery system only allows for 
retrograde implantation. The CoreValve® has not obtained 
FDA approval yet, and
 ■ The Edwards SAPIEN™ valve: A balloon-expandable bovine 
pericardium valve on a stainless-steel stent. The SAPIEN™ 
34
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FIGURE 2: Measurement of the distance between the coronary ostia and the aortic valve annulus.
FIGURE 1: Measurement of the aortic annulus diameter using CT and TEE.
max 24mm
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valve is available in  a 23mm and 26mm prosthesis size and can 
be implanted either transfemorally or transapically. The new 
generation is the SAPIEN XT™ valve, which has some 
modifications in design (cobalt-chrome stent) and also offers a 
29mm valve for the transapical approach. With the SAPIEN™ 
valve a large randomised trial for FDA approval has been 
completed recently(1,24) and approval will probably be granted 
soon. 
BASIC STEPS OF TAVI
Both approaches - the transfemoral (TF) and the transapical (TA) 
AVI - allow for minimally invasive off-pump aortic valve implanta-
tion. Right at the beginning of both approaches a venous back-up 
wire and an arterial sheath should be placed in the femoral vessels 
as a safety net, allowing for immediate conversion (femoral-femoral, 
percutaneous cannulation) to cardio-pulmonary bypass, in case of 
complications.(25)
For TF-AVI both femoral arteries are punctured: One for the device 
implantation and the other for the pigtail catheter. After retro-
grade crossing of the native aortic valve a balloon valvuloplasty is 
performed under rapid ventricular pacing. After haemodynamic 
recovery the prepared valve on its device is introduced and 
positioned under fluoroscopic control. Once a good position is 
confirmed, the valve is deployed under a second brief episode of 
rapid ventricular pacing. After implantation the valve function is 
assessed by either fluoroscopy and/or by TEE. If any significant 
paravalvular leak is noticed it is possible to re-balloon the valve with 
a slightly larger balloon. After removing the delivery sheath, the 
femoral artery has to be closed either surgically or by using a 
closure device (for example Prostar XL™, Abbott Vascular Devices, 
Redwood City California). 
Potential advantages of the TF approach are the avoidance of a 
mini-thoracotomy and that it can be performed without general 
anaesthesia. When using local anaesthesia it is not possible to use 
intra-operative TEE.
TA-AVI is performed through a 5cm left lateral mini-thoracotomy 
in the mid-clavicular line in the 5th or 6th intercostal space. After 
opening  the pericardium, the apex is secured with 2 Teflon pleget-
ted purse-strings followed by apical puncture. Then, the native 
aortic valve is crossed antegrade with a soft guide wire, which is 
changed to a super-stiff wire positioned down into the descending 
aorta. The femoral artery is punctured and through the sheath 
the pigtail catheter is positioned just above the aortic valve. This will 
act as a safety net for rapid CPB initiation if needed during the 
procedure.
The valvuloplasty balloon is now introduced through the apical 
guide wire and the valvuloplasty is performed under rapid ventricular 
pacing. Again, after haemodynamic recovery, the prepared valve 
with its delivery system is inserted through the apex and deployed 
under fluoroscopic guidance. Valve function and position is again 
assessed by TEE and fluoroscopy and similar to TF procedures re-
ballooning might be indicated in case of significant paravalvular 
leaks. After the removal of all sheaths and guide wires, the apex is 
closed with the prepared purse-strings. A detailed step-by-step 
description for TA-AVI has been published earlier.(26)
Advantages of the TA approach are the short distance between the 
apex and the aortic valve, which might allow for a more precise 
implantation and there is no limitation in sheath diameter. The 
avoidance of the retrograde crossing of the aortic arch is another 
great advantage of TA-AVI and it might be reflected by the trend 
towards lower stroke rates with TA.(27-29)
PATIENT OUTCOME AFTER TAVI
Since the beginning of TAVI experience it has evolved to a 
standardised and reproducible technique in specialised centres. The 
overall mortality for TAVI in larger studies varies now between 3 
and 11%.(1,24,30-33) An explanation for the range in mortality might 
be the patient selection. The good outcome from the PARTNER 
(Placement of AoRTic TraNscathetER Valve) trials may result from 
the fact that most of the patients were on a waiting list and the 
sicker patients might have died before the procedure due to their 
co-morbidities. In Europe TAVI has now become established as 
an “all-comers” treatment with even emergency TAVI procedures 
being performed, which might result in worse outcome when 
compared to highly selected series. 
For post-operative aortic regurgitation >1+ the range is even wider. 
It varies between 4% and 18%.(1,24,29,31,34-39) Besides the clinical 
outcome, the quality of life in this elderly high risk patient group is 
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also very important. It has already been demonstrated that TAVI 
leads to an improvement in quality of life, which is comparable with 
an elderly healthy matched population.(40,41)
When comparing TA versus TF, some studies show a trend to-
wards higher mortality in TA patients. A closer look to the risk 
profile of the patients in most of these studies reveals the reason 
for this difference: Many centres have a “TF first” strategy, where 
TA is only performed, when TF is not possible. This leads to a 
higher risk profile in the TA group and this again leads to worse 
outcome.(1,24,29,31,42) Besides the relatively lower risk profile in the TF 
population there is a trend towards higher incidence of peri-
operative strokes and most notably a higher incidence of post-
operative complications in the conducting system leading to an 
incidence of post-operative pacemaker implantation in up to 39% 
of TF patients whenever a CoreValve prosthesis is used.(27,29,31,39,43)
With the PARTNER trial the first randomised controlled com-
parison between TAVI, medical treatment and conventional AVR 
was performed. The results once again demonstrated the poor 
outcome for patients with severe symptomatic AS who receive 
only medical treatment as standard therapy. Their 1-year survival 
was 49.3% versus 69.3% for TAVI. Regarding cardiac symptoms 
the incidence of NYHA Class III-IV among the 1-year survivors 
was lower with TAVI compared to standard therapy.(1) In cohort A 
of the PARTNER trial, TAVI was compared to conventional AVR 
and it demonstrated a better 30-day survival for TAVI (96.5% vs. 
93.5%), but a comparable survival after one year (75.8% for TAVI 
vs. 73.2% for AVR).(24)
FUTURE PERSPECTIVES
The concept of TAVI itself and the associated TAVI devices are at 
a very early stage. Therefore it is not possible to draw any conclusion 
about long term durability or outcome. For this reason TAVI should 
remain restricted as an alternative treatment option for elderly high 
risk patients only. Based on the currently available data there is no 
rationale to expand the indication for TAVI to younger patient 
groups.
New indications for TAVI include degenerated xenografts in the 
aortic position, as well as in the mitral or even the tricuspid position. 
These so called valve-in-valve procedures have been performed by 
some centres and seem to lead to good results.(19-21,44)
Several new transcatheter valves with different features are being 
developed. The JenaValve™ and the Symetis ACURATE™ are 
valve systems that have recently obtained CE-mark approval while 
their pivotal trials have been completed. Both valves are initially 
designed for the TA approach with a transfemoral version under 
development. Both are porcine valves on a self-expandable nitinol 
stent and allow for anatomical orientation of the valve prosthesis 
inside the native annulus. A new valve for the TF approach is the 
Portico™ from St Jude Medical. Its pivotal trial will start soon. There 
are a huge number of other new valve designs from different 
companies, but most of them are still at the level of animal feasi-
bility studies.
There is also some development for the 2 available valve types: The 
CoreValve® system recently underwent a modification to ease 
precise valve deployment and a larger CoreValve® (31mm) has 
been introduced recently. With every new development the sheath 
diameter is decreasing, leading to less frequent major vessel 
complications. The Edwards SAPIEN™ valve is in its second 
generation, as the SAPIEN XT™ with some stent and leaflet 
modifications and an additional 29mm transapical valve. The sheath 
diameter for the TF approach of the SAPIEN™ was also decreased 
over the last years. The newest generation (Esheath™) – an 
expandable sheath which could result in even smaller diameters - 
has entered first clinical trials.
The transaortic aortic valve implantation has been introduced as an 
alternative approach for implanting the CoreValve® prosthesis in 
patients with pronounced peripheral vascular disease where a 
transfemoral approach is not possible. After performing either an 
upper partial sternotomy or a parasternal mini-thoracotomy, the 
ascending aorta is punctured and the valve is implanted retrogradely 
analogous to the transfemoral approach.(45)
THE HEART TEAM AND THE SURGEON’S ROLE
TAVI combines imaging, interventional techniques, surgical tech-
niques and general treatment of elderly high risk patients. This 
makes it a complex procedure, which should be performed by a 
“heart team” including cardiac surgeons, cardiologist and cardiac 
anaesthetists. In our opinion, establishing a successful TAVI pro-
gramme requires launching such a heart team. Every member of the 
team equally contributes his competence to this team. The cardi-
ologists are trained in catheterisation including the handling of the 
THE SURGEON’S ROLE IN TAVI
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fluoroscopic system. This is not only important for the TAVI 
procedure itself, but also for controlling some potential com-
plications of the procedure, like occlusion of the coronaries.
The cardiac anaesthetists are routinely trained in performing intra-
operative TEE and haemodynamic management.
The cardiac surgeons are probably most experienced in treating 
aortic valve stenosis. Over the last decades the cardiac surgeons 
gained a wide knowledge of the pathology and anatomy of the 
aortic valve by conventional open heart AVR. This knowledge is 
not only important during the TAVI procedure itself, but also for 
pre-operative patient selection. The surgical experience also plays 
a role in pre-operative patient’s risk assessment. If a patient has 
some co-morbidities that are not represented by the typical risk 
scoring systems, it is important to identify these as potential risk 
factors and to evaluate if this specific patient is at high risk for 
conventional AVR. For the TA approach it is of course mandatory 
to have some surgical skills for the mini-thoracotomy, the apical 
exposure and closure. Especially if any complication, such as apical 
bleeding, occurs during TA access  a cardiac surgeon would be able 
to solve it. The experience of a cardiac surgeon is important in 
case of major complications for both the TA and TF approach. The 
need for cardio-pulmonary bypass should always be an option, as 
well as conversion to conventional open-heart surgery (AVR, 
bypass grafting, replacement of the ascending aorta or annular 
rupture). Another possible complication is a tear or rupture of the 
femoral vessels, which might require a surgical cut-down and repair.
In summary, a TAVI procedure should not be performed without a 
cardiac surgeon. TF-AVI is not a purely “cardiologist’s cath lab 
procedure” and neither should TA-AVI  be performed by cardiac 
surgeons only.
TAVI is not the only new catheter-based treatment option for 
cardiac diseases former exclusively treated by cardiac surgeons. 
New devices for the mitral valve (MitraClip e.g.) are also available. 
Due to these changes in treatment options, it might become 
important for cardiac surgeons to gain some “wire skills” in future. 
Some centres have already started a rotation for cardiac surgery 
residents into the cath lab to learn the basics of cardiac cathe-
terisation and even some routine PCI. This may be a good way to 
establish a modern type of cardiac surgeon with the option to 
operate as a catheter-based interventionalist.
CONCLUSION
Transcatheter aortic valve implantation has evolved into a routine 
procedure for elderly high risk patients with severe aortic stenosis 
in specialised centres. It is associated with good outcome. It is truly 
minimally invasive and avoids the use of cardio-pulmonary bypass 
and cardioplegic arrest. Both approaches - the transfemoral and 
the transapical - have their specific advantages, but also some 
approach-related disadvantages. In our opinion there are some 
major advantages for the TA-AVI (for example, better control of 
positioning and implantation and no retrograde crossing of the 
aortic arch), which justifies an even and fair split of cases (TF vs TA) 
within a true “heart team”. No hard data which proves the 
superiority of one approach over the other, is available yet. Over 
the last years the outcome after TAVI has generally improved, as 
more and more centres gain experience in these methods.
TAVI must be a team approach where cardiologists and cardiac 
surgeons play an equal role and should not be performed without 
a cardiac surgeon.
Conflict of interest: none declared.
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